<DOC>
	<DOCNO>NCT01731041</DOCNO>
	<brief_summary>Platelets part blood stick together help form clot . The stickier platelet , great chance heart attack . A clot wrong place lead heart attack stroke . Ticagrelor ( Brilinta ) keep platelet stick together help people heart attack . The American College Cardiology recommend combination aspirin Brilinta one best treatment prevention heart attack , death patient heart attack coronary stent . However , unknown Brilinta may improve work keep platelet stick together give load dose patient already treat Brilinta . A load dose one-time increase dose drug . The purpose study demonstrate whether platelet patient treat Brilinta become less sticky Brilinta re-loaded .</brief_summary>
	<brief_title>Impact Ticagrelor Re-load Pharmacodynamic Profiles</brief_title>
	<detailed_description>A high degree platelet inhibition remain goal peri-interventional long-term anti-thrombotic therapy patient coronary artery disease . Previous observation show patient clopidogrel therapy undergo percutanoues coronary intervention get re-loaded clopidogrel obtain enhanced platelet inhibition . Ticagrelor represent new class nonthienopyridine platelet inhibitor design address limitation current oral antiplatelet therapy , recently approve clinical use . However , date unknown great inhibition platelet aggregation achieve add ticagrelor load dose patient already maintenance ticagrelor therapy ( 90 mg twice daily ) . In addition , manage patient undergoing coronary intervention already chronic ticagrelor therapy regard ticagrelor load emerge clinical question yet explore . Therefore , understand pharmacodynamic implication ticagrelor re-load strategy patient already chronic ticagrelor therapy warrant . The scope present study evaluate impact ticagrelor re-load patient chronic ticagrelor therapy . A total 60 patient randomize one follow two arm treatment : 1 ) 90 mg ticagrelor ; 2 ) 180 mg ticagrelor . Pharmacodynamic assessment perform baseline , 1-hour 4-hour dosing administration . Comparison baseline 4-hour value term platelet P2Y12 reactivity index determine whole blood vasodilator-stimulated phosphoprotein primary end-point study . Secondary endpoint include pharmacodynamic measure .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<criteria>1 . Patients clinical indication ticagrelor therapy ( 90mg/bid ) 2 . On treatment ticagrelor 90mg twice daily least 14 day 3 . Age 18 80 year 4 . On aspirin &lt; 100mg/day 1 . History intracranial bleeding 2 . Severe hepatic impairment ( ALT &gt; 2.5 time upper limit normal ) 3 . Active bleeding propensity bleed 4 . Recent antiplatelet treatment ( &lt; 14 day ) glycoprotein IIb/IIIa antagonist 6 . Platelet count &lt; 80x106/mL 7 . Hemodynamic instability 8 . Serum creatinine &lt; 30 mL/min 9 . On treatment oral anticoagulant ( Vitamin K antagonist , dabigatran , rivaroxaban ) 10 . Patients sick sinus syndrome II III degree AV block without pacemaker protection 12 . Drugs interfere CYP3A4 metabolism ( avoid interaction Ticagrelor ) : ketoconazole , itraconazole , voriconazole , clarithromicin , nefazodone , ritonavir , saquinavir , nelfinavir , indinavir , atazanavir telithromizycin 13 . Hemoglobin &lt; 10g/dL 14 . Pregnant female [ woman childbearing age must use reliable birth control ( i.e . oral contraceptive ) participate study ] .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>coronary disease , platelet function , platelet inhibitor</keyword>
</DOC>